CN101160402B - 肿瘤特异性抗体和细胞表面蛋白质 - Google Patents

肿瘤特异性抗体和细胞表面蛋白质 Download PDF

Info

Publication number
CN101160402B
CN101160402B CN2005800485228A CN200580048522A CN101160402B CN 101160402 B CN101160402 B CN 101160402B CN 2005800485228 A CN2005800485228 A CN 2005800485228A CN 200580048522 A CN200580048522 A CN 200580048522A CN 101160402 B CN101160402 B CN 101160402B
Authority
CN
China
Prior art keywords
cancer
seq
varient
relevant
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800485228A
Other languages
English (en)
Chinese (zh)
Other versions
CN101160402A (zh
Inventor
尼古拉斯·R·格罗沃
格伦·麦克唐纳
乔伊斯林·恩特韦斯特尔
吉恩尼克·西兹尔尤
弗兰西娜·C·查海尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Viventia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Biotech Inc filed Critical Viventia Biotech Inc
Publication of CN101160402A publication Critical patent/CN101160402A/zh
Application granted granted Critical
Publication of CN101160402B publication Critical patent/CN101160402B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
CN2005800485228A 2004-12-21 2005-12-21 肿瘤特异性抗体和细胞表面蛋白质 Expired - Fee Related CN101160402B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63744804P 2004-12-21 2004-12-21
US60/637,448 2004-12-21
PCT/CA2005/001953 WO2006066408A1 (en) 2004-12-21 2005-12-21 Cancer specific antibody and cell surface proteins

Publications (2)

Publication Number Publication Date
CN101160402A CN101160402A (zh) 2008-04-09
CN101160402B true CN101160402B (zh) 2013-06-05

Family

ID=36601325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800485228A Expired - Fee Related CN101160402B (zh) 2004-12-21 2005-12-21 肿瘤特异性抗体和细胞表面蛋白质

Country Status (12)

Country Link
US (2) US8084576B2 (enExample)
EP (1) EP1833968B1 (enExample)
JP (2) JP5143566B2 (enExample)
CN (1) CN101160402B (enExample)
AU (1) AU2005318836B2 (enExample)
CA (1) CA2591768C (enExample)
ES (1) ES2421558T3 (enExample)
IL (1) IL183958A (enExample)
NZ (1) NZ556055A (enExample)
RU (1) RU2007127889A (enExample)
WO (1) WO2006066408A1 (enExample)
ZA (1) ZA200705837B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508670B1 (pt) 2004-03-19 2023-01-24 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas, usos das referidas citotoxinas para o tratamento de câncer, composição farmacêutica, processo de preparação de produto farmacêutico, ácidos nucléicos e peptídeos de epítopo de célula t
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9636329B2 (en) * 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
MX2016004239A (es) * 2013-10-02 2016-11-14 Viventia Bio Inc Anticuerpos anti-epcam y métodos de uso.
WO2016194769A1 (ja) * 2015-05-29 2016-12-08 富士フイルム株式会社 ポリイミド前駆体組成物、感光性樹脂組成物、硬化膜、硬化膜の製造方法、半導体デバイスおよびポリイミド前駆体組成物の製造方法
US10781260B2 (en) 2016-08-08 2020-09-22 Sorrento Therapeutics, Inc. Anti-OX40 binding proteins
CN108101988B (zh) * 2016-11-24 2021-09-07 复旦大学 针对cd16的全人源单域抗体、其抗原结合片段及应用
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
WO2020086830A2 (en) * 2018-10-26 2020-04-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN114807054B (zh) * 2022-06-24 2022-09-13 北京索莱宝科技有限公司 小鼠抗人IgG单抗杂交瘤细胞株、抗体、抗体组合物及试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
JPH06141884A (ja) * 1992-11-06 1994-05-24 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
WO1994016726A1 (en) 1993-01-22 1994-08-04 Hygeia Pharmaceuticals, Inc. Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
EP0975762B1 (en) 1997-06-06 2011-10-05 PanGenetics B.V. Type-1 ribosome-inactivating protein
US20030228592A1 (en) * 1997-10-01 2003-12-11 St. Vincent's Institute Of Medical Research Human facilitative glucose transport protein GLUT8
WO2001004145A2 (en) 1999-07-14 2001-01-18 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US7001735B2 (en) 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
EP1556088A2 (en) 2002-10-29 2005-07-27 Engene, Inc. Compositions for cancer treatment
WO2004095099A1 (en) * 2003-04-01 2004-11-04 Corning Incorporated Photonic band gap optical fiber

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aotsuka Y, et al.Identification of a malignant cell associated antigen recognized by a human monoclonal antibody.《Eur J Cancer Clin Oncol》.1988,第24卷(第5期),第829-838页. *
Fenstermaker RA, et al.Immunotherapeutic Strategies for Malignant Glioma.《Cancer Control》.2004,第11卷(第3期),第181-191页. *
Hagiwara H, et al.Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG.《Human Antibodies》.2001,第10卷第77-82页. *

Also Published As

Publication number Publication date
EP1833968A1 (en) 2007-09-19
CA2591768A1 (en) 2006-06-29
US8697075B2 (en) 2014-04-15
ZA200705837B (en) 2008-05-28
US20120128723A1 (en) 2012-05-24
EP1833968A4 (en) 2009-09-16
CA2591768C (en) 2016-06-14
AU2005318836A1 (en) 2006-06-29
RU2007127889A (ru) 2009-01-27
JP2013063066A (ja) 2013-04-11
CN101160402A (zh) 2008-04-09
EP1833968B1 (en) 2013-04-17
IL183958A (en) 2012-02-29
AU2005318836B2 (en) 2012-03-22
JP2008523825A (ja) 2008-07-10
NZ556055A (en) 2009-12-24
IL183958A0 (en) 2007-10-31
US8084576B2 (en) 2011-12-27
US20100254982A1 (en) 2010-10-07
WO2006066408A1 (en) 2006-06-29
JP5143566B2 (ja) 2013-02-13
ES2421558T3 (es) 2013-09-03

Similar Documents

Publication Publication Date Title
CN101044242B (zh) 肿瘤特异性抗体
US8999334B2 (en) Antibody conjugates against variant NFKBIB and uses thereof
US8697075B2 (en) Cancer specific antibody and cell surface proteins
HK1202299A1 (en) Novel cancer-associated antigen
HK1114124A (en) Cancer specific antibody and cell surface proteins
HK1151973A (en) Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114124

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114124

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: VIVENTIA BIOTECHNOLOGY INC.

Free format text: FORMER OWNER: VIVENTIA BIOTECH INC.

Effective date: 20140714

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140714

Address after: Manitoba

Patentee after: VIVENTIA BIOTECHNOLOGIES INC.

Address before: Ontario

Patentee before: Viventia Biotech Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130605

Termination date: 20171221

CF01 Termination of patent right due to non-payment of annual fee